Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Expected to Announce Quarterly Sales of $40.90 Million

Equities analysts forecast that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will announce $40.90 million in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Ultragenyx Pharmaceutical’s earnings, with the lowest sales estimate coming in at $39.75 million and the highest estimate coming in at $45.00 million. Ultragenyx Pharmaceutical reported sales of $24.15 million during the same quarter last year, which indicates a positive year over year growth rate of 69.4%. The business is expected to announce its next earnings report on Thursday, August 6th.

On average, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $179.15 million for the current financial year, with estimates ranging from $160.88 million to $200.80 million. For the next financial year, analysts anticipate that the business will report sales of $288.43 million, with estimates ranging from $230.52 million to $340.32 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.91) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.23). Ultragenyx Pharmaceutical had a negative net margin of 348.78% and a negative return on equity of 60.65%. The firm had revenue of $36.31 million for the quarter, compared to the consensus estimate of $36.74 million. During the same quarter last year, the firm earned ($1.82) EPS. The company’s revenue was up 99.8% on a year-over-year basis.

A number of analysts have recently issued reports on RARE shares. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating and set a $61.00 target price for the company in a research note on Thursday, April 16th. Wedbush boosted their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $91.00 and gave the company an “outperform” rating in a research note on Wednesday. Canaccord Genuity boosted their target price on shares of Ultragenyx Pharmaceutical from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Thursday. Citigroup boosted their target price on shares of Ultragenyx Pharmaceutical from $53.00 to $66.00 and gave the company a “neutral” rating in a research note on Friday, May 8th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Ultragenyx Pharmaceutical from $76.00 to $84.00 and gave the company an “overweight” rating in a research note on Wednesday. Four research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $80.00.

In other news, Director Matthew K. Fust sold 1,875 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The shares were sold at an average price of $65.00, for a total transaction of $121,875.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Theodore Alan Huizenga sold 2,461 shares of the company’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $71.00, for a total transaction of $174,731.00. Following the transaction, the senior vice president now owns 18,719 shares in the company, valued at approximately $1,329,049. The disclosure for this sale can be found here. Over the last three months, insiders have sold 26,555 shares of company stock valued at $1,942,395. Insiders own 8.20% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of RARE. Victory Capital Management Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 17.2% during the fourth quarter. Victory Capital Management Inc. now owns 7,400 shares of the biopharmaceutical company’s stock valued at $316,000 after acquiring an additional 1,087 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 1.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 335,579 shares of the biopharmaceutical company’s stock valued at $14,333,000 after acquiring an additional 5,886 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of Ultragenyx Pharmaceutical by 1,976.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 706 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 672 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $114,000. Finally, Bank of Montreal Can increased its holdings in Ultragenyx Pharmaceutical by 37.0% in the 4th quarter. Bank of Montreal Can now owns 7,059 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 1,906 shares during the period. Hedge funds and other institutional investors own 99.91% of the company’s stock.

Shares of RARE traded up $1.39 during trading hours on Wednesday, reaching $86.04. 665,237 shares of the company traded hands, compared to its average volume of 626,550. The firm has a market cap of $5.13 billion, a price-to-earnings ratio of -11.71 and a beta of 2.28. Ultragenyx Pharmaceutical has a 12-month low of $31.99 and a 12-month high of $86.11. The company has a current ratio of 4.54, a quick ratio of 4.49 and a debt-to-equity ratio of 0.06. The stock’s fifty day moving average price is $72.53 and its 200 day moving average price is $57.90.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.

Recommended Story: Why does a company issue an IPO?

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.